Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Sharps Technology Inc. Warrant (STSSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: STSSW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -68.75% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.92 | 52 Weeks Range 0.01 - 0.14 | Updated Date 05/24/2025 |
52 Weeks Range 0.01 - 0.14 | Updated Date 05/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.96 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -42.67% | Return on Equity (TTM) -75.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 1017855 |
Shares Outstanding - | Shares Floating 1017855 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Sharps Technology Inc. Warrant
Company Overview
History and Background
Sharps Technology, Inc. focuses on developing and manufacturing safety syringe products. While a warrant isn't a company, it's a derivative contract giving the holder the right to purchase the underlying stock (STSS) at a specified price before a specified date.
Core Business Areas
- Safety Syringe Technology: Development, manufacturing, and sale of innovative safety syringes designed to prevent needlestick injuries.
Leadership and Structure
Information about the warrant (STSSW) itself doesn't involve leadership or organizational structure. These aspects pertain to the underlying company, Sharps Technology (STSS).
Top Products and Market Share
Key Offerings
- Safety Syringes: Sharps Technology aims to provide innovative safety syringes which could help in needlestick prevention. Market share data is limited and difficult to determine, as the underlying company STSS is emerging. Competitors include established medical device companies such as Becton Dickinson (BDX) and Smiths Medical.
Market Dynamics
Industry Overview
The medical device industry, particularly the segment for injection devices, is driven by increasing awareness of healthcare worker safety and regulations promoting safer practices. Growth is expected due to the need to prevent bloodborne pathogen transmission.
Positioning
Sharps Technology seeks to capture a share of the safety syringe market by offering innovative solutions. Competitive advantages depend on the efficacy, cost-effectiveness, and regulatory approvals of their products.
Total Addressable Market (TAM)
The global syringe and needle market is estimated to be multi-billion dollars. Sharps Technology's success will depend on its ability to effectively penetrate this market and secure a significant share.
Upturn SWOT Analysis
Strengths
- Innovative safety syringe technology
- Focus on needlestick prevention
- Potential to disrupt existing market
Weaknesses
- Limited market share
- Reliance on regulatory approvals
- Competition from established players
- Dependence on raising further capital
Opportunities
- Growing demand for safety syringes
- Expansion into new markets
- Strategic partnerships
- New regulations mandating safer injection practices.
Threats
- Intense competition
- Technological advancements by competitors
- Regulatory hurdles
- Economic downturn affecting healthcare spending.
Competitors and Market Share
Key Competitors
- BDX
- SYK
- MMM
Competitive Landscape
Sharps Technology is a smaller player compared to established competitors. The warrant is impacted greatly based on STSS success and developments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth of the warrant mirrors the stock performance of Sharps Technology (STSS).
Future Projections: Future projections for the warrant depend on analysts' estimates for Sharps Technology's (STSS) growth, market adoption of its products, and overall industry trends.
Recent Initiatives: Recent initiatives of Sharps Technology (STSS) should be monitored as they directly impact the value of the warrant.
Summary
The Sharps Technology warrant (STSSW) represents a speculative investment tied directly to the future success of Sharps Technology (STSS). The company is aiming to disrupt the safety syringe market with innovative technology. However, they face strong competition from established players and regulatory challenges. The warrant's value will fluctuate based on STSS's operational performance and market sentiment. Investors should carefully assess the risks and potential rewards of investing in both the underlying stock and its warrant.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Market Research Reports
- Financial News Outlets
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sharps Technology Inc. Warrant
Exchange NASDAQ | Headquaters Melville, NY, United States | ||
IPO Launch date 2022-04-14 | CEO & Director Mr. Robert M. Hayes | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 55 | Website https://sharpstechnology.com |
Full time employees 55 | Website https://sharpstechnology.com | ||
Sharps Technology, Inc., a medical device and pharmaceutical packaging company, engages in the design, research and development, manufacturing, and commercialization of safety syringe products in the United States. The company provides safety syringe products comprising Securgard, Sologard, and Sharps Provensa that are ultra-low waste syringes for passive, and safety and reuse prevention features, as well as develops prefillable syringe systems. The company was incorporated in 2017 and is based in Melville, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.